Valneva SE
PAR:VLA
Valneva SE
Gross Profit
Valneva SE
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valneva SE
PAR:VLA
|
Gross Profit
€88.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Gross Profit
€21.9m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Gross Profit
€81.8m
|
CAGR 3-Years
177%
|
CAGR 5-Years
70%
|
CAGR 10-Years
31%
|
|
|
Inventiva SA
PAR:IVA
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Gross Profit
€67.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
27%
|
CAGR 10-Years
17%
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Valneva SE
Glance View
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
See Also
What is Valneva SE's Gross Profit?
Gross Profit
88.9m
EUR
Based on the financial report for Sep 30, 2024, Valneva SE's Gross Profit amounts to 88.9m EUR.
What is Valneva SE's Gross Profit growth rate?
Gross Profit CAGR 1Y
-46%
Over the last year, the Gross Profit growth was -46%.
You don't have any saved screeners yet